Comparative Pharmacology
Head-to-head clinical analysis: CEFOTAN IN PLASTIC CONTAINER versus CEFOTAXIME AND DEXTROSE 2 4 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTAN IN PLASTIC CONTAINER versus CEFOTAXIME AND DEXTROSE 2 4 IN PLASTIC CONTAINER.
CEFOTAN IN PLASTIC CONTAINER vs CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotetan is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and cross-linking of peptidoglycan. It has broad-spectrum activity against gram-negative and gram-positive bacteria, including anaerobes, and is resistant to beta-lactamases.
Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis.
1 to 2 g intravenously or intramuscularly every 12 hours for 5 to 10 days. Maximum dose 6 g daily.
1-2 g IV every 6-8 hours; maximum 12 g/day.
None Documented
None Documented
2.8-3.2 hours in normal renal function; prolonged to 12-30 hours in severe renal impairment (CrCl <10 mL/min).
0.8-1.4 hours (normal renal function); ~2-6 hours in renal impairment; prolonged in neonates and elderly
Primarily renal (76-85% unchanged in urine via glomerular filtration and tubular secretion); biliary excretion accounts for <10%, with small amounts in feces.
Renal: 50-60% unchanged; biliary: 20-30%; fecal: <5%
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic